Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
Authors
José Luis Lledó-Navarro (ORCID: https://orcid.org/0000-0001-7973-3503)
Ion Agirrezabal (ORCID: https://orcid.org/0000-0003-3170-7845)
Manuel de la Torre‐Aláez (ORCID: https://orcid.org/0000-0002-1972-3933)
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
José Luis Lledó-Navarro, Ion Agirrezabal, Manuel de la Torre‐Aláez, Marı́a Varela et al.
Citations
1 citations
Journal
Journal of Patient-Reported Outcomes
Topics
Hepatocellular Carcinoma Treatment and Prognosis
Field-Weighted Citation Impact (FWCI)
1.32
article
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
José Luis Lledó-Navarro, Ion Agirrezabal, Manuel de la Torre‐Aláez, Marı́a Varela, Sara Lorente, Ana Matilla, Gemma Iserte, Milagros Testillano, José Ignacio Bilbao, Mercedes Iñarrairaegui, Johannes Pöhlmann, Macarena Rodríguez‐Fraile, Carlos Gómez-Martín, Josepmaria Argemí, Richard Fulton Pollock, Laura Márquez, María Reig, Bruno Sangro, Juan Ignacio Arenas
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Patient-Reported OutcomesVol. 9(1)
Institutions
Universidad de Alcalá (ES), Hospital General Universitario Gregorio Marañón (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario 12 De Octubre (ES), Hospital Clínic de Barcelona (ES), Sirtex (Germany) (DE), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Hospital Universitario Central de Asturias (ES), Clinica Universidad de Navarra (ES), Hospital Clínico Universitario Lozano Blesa (ES), Hospital de Cruces (ES), A-T Society (GB), Hospital Universitario Ramón y Cajal (ES), Covalence Research, Universitat de Barcelona (ES)
Funders
Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Boston Scientific Corporation, Eisai, Ipsen, Sirtex Medical